Clinical Trials
13
Active:2
Completed:7
Trial Phases
4 Phases
Phase 2:4
Phase 3:4
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (36.4%)Phase 3
4 (36.4%)Not Applicable
2 (18.2%)Phase 4
1 (9.1%)Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders
Phase 3
Active, not recruiting
- Conditions
- Harm ReductionSmoking Cessation
- Interventions
- Other: NJOY e-cigaretteOther: on!
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT06554873
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
Evaluate Harm Reduction Products As a Second Line Intervention for Adult Smokers Who Do Not Quit with NRT
Phase 3
Terminated
- Conditions
- Smoking CessationHarm Reduction
- Interventions
- Other: on!Other: BIDI e-cigarette
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT06088862
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine
Phase 2
Recruiting
- Conditions
- Harm ReductionSmoking Cessation
- Interventions
- Other: Juul e-cigarette
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT05994703
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
Exploratory Study of Switching From Combustible Cigarettes to the BIDI E-cigarette
Not Applicable
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT05855343
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
Phase 3
Active, not recruiting
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 180
- Registration Number
- NCT05205811
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found